Nephrocare Health Services Ltd

Nephrocare Health Services will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Nephrocare Health Services announced that the 17th Annual General Meeting(AGM) of the company will be held on 12 August 2026.

Nephrocare Health Services has allotted 2,18,297 equity shares under ESOP on 14 June 2026. Consequently, the paid up equity share capital has increased to Rs 20,11,18,028, comprising 10,05,59,014 equity shares of face value of Rs 2/- each.

Nephrocare Health Care Services, Philippines Inc., an overseas step-down wholly-owned subsidiary of Nephrocare Health Services, has entered into an Asset Transfer Agreement (ATA) dated 09 June 2026 with Amica Healthcare System Corporation for the acquisition of identified assets relating to a dialysis center located at Dona Soledad, Don Bosco, Paranaque City, Philippines, for a total consideration of PhP 32,640,000, subject to the terms and conditions set out therein.

The agreement is to acquire identified assets related to a dialysis centre in Quezon City, Philippines. The acquisition pertains to a dialysis facility located at Duyan-Duyan, Project 3, Quezon City, and is being undertaken for a total consideration of PHP 30 million. The company said the transaction is aimed at expanding its dialysis care footprint in the Philippines and will be executed in accordance with the terms and conditions of the agreement. Nephrocare clarified that the seller is not related to the company, its promoters, or promoter group entities. The transaction does not qualify as a related-party transaction and does not involve any special rights or share issuance arrangements. Nephrocare Health Services provides end-to-end dialysis care through a wide network of clinics across India and select international markets. The compnay's consolidated net profit rose 22.1% to Rs 30.37 crore on 21.2% increase in revenue from operations to Rs 265.62 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Net profit of Nephrocare Health Services rose 22.12% to Rs 30.37 crore in the quarter ended March 2026 as against Rs 24.87 crore during the previous quarter ended March 2025. Sales rose 21.18% to Rs 265.62 crore in the quarter ended March 2026 as against Rs 219.19 crore during the previous quarter ended March 2025. For the full year,net profit rose 14.52% to Rs 76.84 crore in the year ended March 2026 as against Rs 67.10 crore during the previous year ended March 2025. Sales rose 32.16% to Rs 998.85 crore in the year ended March 2026 as against Rs 755.81 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales265.62219.19 21 998.85755.81 32 OPM %19.0823.40 -22.4122.05 - PBDT59.0649.30 20 188.14159.91 18 PBT33.2229.92 11 97.4787.44 11 NP30.3724.87 22 76.8467.10 15 Powered by Capital Market - Live

Nephrocare Health Services has designated Prashant Vinodkumar Goenka, Chief Financial Officer of the Company, as the Chief Risk Officer (CRO) of the Company, in addition to his existing responsibilities, with immediate effect.

Net profit of Nephrocare Health Services rose 60.32% to Rs 32.24 crore in the quarter ended December 2025 as against Rs 20.11 crore during the previous quarter ended December 2024. Sales rose 31.67% to Rs 259.73 crore in the quarter ended December 2025 as against Rs 197.26 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales259.73197.26 32 OPM %23.4322.35 - PBDT58.2244.61 31 PBT36.3626.44 38 NP32.2420.11 60 Powered by Capital Market - Live

Nephrocare Health Services will hold a meeting of the Board of Directors of the Company on 10 February 2026.Powered by Capital Market - Live

The stock debuted at Rs 491.70 on the BSE, exhibiting a premium of 6.89% over the issue price. So far, the stock has hit a high of 498.70 and a low of 478. On the BSE, over 12.30 lakh shares of the company were traded in the counter so far. Intial Publifc Offer (IPO) of Nephrocare Health Services received bids for 18,68,94,880 shares as against 1,33,87,854 shares on offer. The issue was subscribed 13.96 times. The IPO comprised fresh issue of equity shares worth up to Rs 353.4 crore and an offer for sale of 1,12,53,102 equity shares aggregating up to Rs 517.64 crore by existing shareholders including Investcorp Private Equity Fund II, Healthcare Parent, Investcorp Growth Opportunity Fund, Edoras Investment Holdings, among others. The objectives for the fresh issue include Rs 129.1 crore for capital expenditure for opening new dialysis clinics in India, Rs 135.99 crore for pre-payment, or repayment, of certain borrowings, and remaining amount for general corporate purpose. The promoters are Vikram Vuppala, BVP Trust, Edoras Investment Holdings, HPL, IPEF II and IGOF. The promoters and promoter group hold an aggregate of 7,31,03,833 equity shares, aggregating to 78.9% of the pre-offer issued and paid-up equity share capital. Their post IPO shareholding is expected to be around 66.72%. Ahead of the IPO, Nephrocare Health Services on 2 December 2025, the company raised Rs 2,439.54 crore from anchor investors, by allotting 21.97 lakh crore shares at Rs 111 each to 125 anchor investors. Nephrocare Health Services offers comprehensive dialysis care through its clinic network, covering diagnosis, treatment, and wellness programs. Its offerings include haemodialysis, home and mobile dialysis, hemodiafiltration, holiday dialysis, dialysis on call, and dialysis on wheels, supported by an in-house pharmacy, providing patients with convenient and holistic care. In India, the company has a presence across 288 cities in 21 States and 4 Union Territories. Approximately 77.35% of its clinics were in tier II and tier III cities, addressing a critical need in underserved regions. The company operates a network of 519 clinics, with 51 clinics internationally across the Philippines, Uzbekistan and Nepal, as of September 30, 2025 India operations contributed 60.04% of revenue, international operations 39.96% in H1 FY2026. The company's dialysis machine count increased to 5,562 as of September 30, 2025, from 5,068 on March 31, 2025. For the six months ended 30 September 2025, the firm recorded a consolidated net profit of Rs 14.23 crore and sales of Rs 473.50 crore.Powered by Capital Market - Live